BRIEF-Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir
Feb 13 Aviragen Therapeutics Inc
* Aviragen Therapeutics announces top-line results from phase 2b SPIRITUS trial of Vapendavir
* Aviragen Therapeutics Inc - SPIRITUS trial did not meet its primary endpoint
* Aviragen - Vapendavir did not demonstrate a statistically significant reduction in asthma control questionnaire-6 (ACQ-6) at day 14, primary endpoint
* Aviragen - secondary endpoints did not show significant differences between treatment groups and placebo
* Aviragen - Vapendavir was shown to be generally well tolerated and safety profile was consistent with previous clinical studies
* Aviragen - Vapendavir did not show a significant reduction in asthma control questionnaire-6 for either 264 mg or 528 mg cohorts compared to placebo Source text for Eikon: Further company coverage: